key: cord-0845536-gisv2n6x
authors: Shanthikumar, Shivanthan; Gower, William A.; Abts, Matthew; Liptzin, Deborah R.; Fiorino, Elizabeth K.; Stone, Anne; Srinivasan, Saumini; Vece, Timothy J.; Akil, Nour; Cole, Theresa; Cooke, Kenneth R.; Goldfarb, Samuel B.
title: Pulmonary surveillance in pediatric hematopoietic stem cell transplant: A multinational multidisciplinary survey
date: 2021-07-28
journal: Cancer Rep (Hoboken)
DOI: 10.1002/cnr2.1501
sha: 0b4c9c8986ec01d5705bff0b28e3ad571b33be3c
doc_id: 845536
cord_uid: gisv2n6x

BACKGROUND: Hematopoietic Stem Cell Transplant (HSCT) is an established treatment for malignant and non‐malignant conditions and pulmonary disease is a leading cause of late term morbidity and mortality. Accurate and early detection of pulmonary complications is a critical step in improving long term outcomes. Existing guidelines for surveillance of pulmonary complications post‐HSCT contain conflicting recommendations. AIM: To determine the breadth of current practice in monitoring for pulmonary complications of pediatric HSCT. METHODS: An institutional review board approved, online, anonymous multiple‐choice survey was distributed to HSCT and pulmonary physicians from the United States of America and Australasia using the REDcap platform. The survey was developed by members of the American Thoracic Society Working Group on Complications of Childhood Cancer, and was designed to assess patient management and service design. RESULTS: A total of 40 (34.8%) responses were received. The majority (62.5%) were pulmonologists, and 82.5% were from the United States of America. In all, 67.5% reported having a protocol for monitoring pulmonary complications and 50.0% reported adhering “well” or “very well” to protocols. Pulmonary function tests (PFTs) most commonly involved spirometry and diffusion capacity for carbon monoxide. The frequency of PFTs varied depending on time post‐HSCT and presence of complications. In all, 55.0% reported a set threshold for a clinically significant change in PFT. CONCLUSIONS: These results illustrate current variation in surveillance for pulmonary complications of pediatric HSCT. The results of this survey will inform development of future guidelines for monitoring of pulmonary complications after pediatric HSCT.

Childhood Cancer, and was designed to assess patient management and service design.

Results: A total of 40 (34.8%) responses were received. The majority (62.5%) were pulmonologists, and 82.5% were from the United States of America. In all, 67.5% reported having a protocol for monitoring pulmonary complications and 50.0% reported adhering "well" or "very well" to protocols. Pulmonary function tests (PFTs) most commonly involved spirometry and diffusion capacity for carbon monoxide. The frequency of PFTs varied depending on time post-HSCT and presence of complications. In all, 55.0% reported a set threshold for a clinically significant change in PFT.

Conclusions: These results illustrate current variation in surveillance for pulmonary complications of pediatric HSCT. The results of this survey will inform development of future guidelines for monitoring of pulmonary complications after pediatric HSCT. 1, 2 The rates of HSCT are increasing, and currently more than 50 000 3 are performed annually worldwide including approximately 1600 HSCTs in the pediatric age group. 4 Survival following HSCT has improved, with reduced relapse-and non-relapse-related mortality over time, [5] [6] [7] and survival expected well into adulthood. The combination of increased HSCT and improved survival means there are increasing numbers of HSCT survivors who need surveillance for late effects of HSCT. 2, 7 A recent study found that adults who underwent HSCT in childhood had a 14.4-fold increased risk for death compared with the general population. 7 Pulmonary complications comprise a leading cause of nonrelapse morbidity and mortality after HSCT. 7, 8 Among children, there are multiple late pulmonary complications of HSCT, including infection, graft vs. host disease (GVHD), pulmonary vascular disease, interstitial fibrosis and others. [9] [10] [11] Two categories of chronic lung disease, defined based on pulmonary function testing (PFT), are observed in the months and years following allogeneic HSCT: obstructive and restrictive lung disease. 10, [12] [13] [14] [15] Obstructive lung disease, most commonly manifests as bronchiolitis obliterans syndrome (BOS) which is the most recognized form of chronic lung disease after HSCT. BOS is characterized by progressive, narrowing and destruction of small airways along with fixed airflow obstruction and is associated with increased morbidity and mortality. 8 The incidence of BOS after HSCT is 4.8%-6.5% [16] [17] [18] with a median time to development of 12.2 months. 19 Restrictive lung disease occurs in a smaller proportion of patients with a median time to diagnosis of 11 months post-HSCT. 20, 21 This pattern is less specific for a single diagnosis, and is often multifactorial, including individuals with previous chest wall/thoracic surgery, radiation therapy, and deconditioning with neuromuscular weakness, as well as patients who develop acute lung injury (e.g. idiopathic pneumonia syndrome) and interstitial lung disease.

The clinical presentation of pulmonary complications of HSCT is often non-specific, and investigations such as PFTs, chest imaging, bronchoscopy with bronchoalveolar lavage, and lung biopsy are employed to elucidate the exact cause. Pulmonary complications can often be detected non-invasively, without ionizing radiation, and at relatively low cost by PFTs prior to the onset of clinical symptoms. This is important because early treatment has been shown to have profound implications for long term pulmonary health. [22] [23] [24] Two pediatric cohorts have examined the efficacy of monitoring pulmonary function testing longitudinally and revealed that compared to clinical signs and symptoms, screening PFTs led to earlier identification of pulmonary complications. 25, 26 Screening for post-HSCT pulmonary complications with PFTs to facilitate early detection and treatment is generally considered standard of care.

Despite consensus that screening for post-HSCT pulmonary complications should occur, existing guidelines include conflicting recommendations regarding which tests should be performed, the frequency of testing and omit recommendations for patients unable to complete PFTs. 1, 2, 27 For example the Children's Oncology Group 2 recommend annual screening with spirometry and diffusion capacity for carbon monoxide (D L CO) only, whereas a multi-society guideline 27 does not specify which tests to use and recommends screening at 6 months post HSCT, 12 months, and then annually with increased frequency in those with graft vs host disease (GVHD). A guideline 1 aimed at patients who underwent HSCT for hemoglobinopathy recommends screening at 3, 6, and 12 months post HSCT and then annually for a further 2 years, with screening involving spirometry, plethysmography and D L CO. In addition, current guidelines do not include tests such as multiple breath washout (MBW) or impulse oscillometry, which may be more sensitive measures of peripheral airway function (where BOS occurs) and are feasible in young children. 28, 29 There is also little guidance for how other investigations, such as CT, bronchoscopy and bronchoalveolar lavage and biopsy should be used. Furthermore, many of these modalities, as well as access to pediatric pulmonology expertise, are not routinely available at all centers worldwide. 30 Considering that early childhood is a critical period for lung development with long-lasting effects into adulthood, 31 optimizing pulmonary health in children post-HSCT is crucial. An opportunity therefore exists to improve screening for pulmonary complications of childhood HSCT at the international level. This was one of the key messages from a recent National Institutes of Health workshop regarding pulmonary complications of HSCT. 32 The workshop specifically called for standardization of lung function testing in this population, including the use of novel methods in the preschool age group.

The current project was established to better understand current multinational clinical practice. It was hypothesized that given the conflicting recommendations in guidelines, that there would be variation in practice between HSCT centers. In addition to intercenter variation, it was also suspected that HSCT physicians and pediatric pulmonologists would differ in their approach to post HSCT patients. As such, the aim was to survey both HSCT physicians and pediatric pulmonologists regarding their current practice of screening for and diagnosing pulmonary complications of HSCT.

Some of the results of this study has been previously reported in the form of an abstract. 33 2 | METHODS 

The survey instrument (see Appendix A) was developed by a core group of members of the American Thoracic Society Working Group 

As data was non-normally distributed, correlations were tested using the Mann Whitney test, with p-values <.05 considered significant. All statistical analyses were performed using GraphPad Prism, version 6.01 (GraphPad Software Inc., La Jolla, California).

The (Table 1 ). year which is summarized in Figure 1 .

The majority of respondents (27/ 

The 

The majority of respondents reported chest computed tomography (CT) scans were performed pre-HSCT (21/40, 52.5%), however most reported they were not routinely repeated post-HSCT (26/40, 65%). Table 4 ) with thoracoscopic being the most common (29/40, 72.5%).

The survey illustrates variation in practices for monitoring pulmonary health of pediatric HSCT survivors. We suspect that this is due to a lack of standardized guidelines, which reflects a paucity of data about which approaches are optimal. It may also reflect differences in access to diagnostic resources. 30 A survey of North American HSCT center directors demonstrated that 71% of centers without a dedicated follow up clinic had an identified pulmonologist they referred patients to, and in centers with a dedicated clinic, a pulmonologist was involved in 84.4% of those clinics. 38 In the current survey, all respondents had access to pediatric pulmonologists, however only 52.5% reported there was an identified pulmonologist for referrals and 52.5% reported routine referral of patients to pediatric pulmonology. A potential explanation for the lower rates in this current survey is differences in practice between adult and pediatric HSCT centers. Follow-up of children who have undergone HSCT is complex and subspecialty expertise is needed.

The ideal scenario would involve at least one dedicated pulmonologist at each center working closely together with HSCT physicians to deliver patient care and develop screening programs and research projects to answer clinically relevant questions.

There are some limitations to the current project. Firstly, use of a survey approach relies on respondents' answers to questions rather than a direct assessment of practices. It would be expensive and impractical to perform in-person assessments of practice across centers on two continents. Our survey concluded just prior to the start of the SARS-CoV-2 pandemic, and thus our results reflect pre-pandemic practices. ACKNOWLEDGMENT N/A.

The authors have no conflicts to disclose. 

Institutional review board approval was obtained from the Royal Children's Hospital, Melbourne, Australia (HREC number 2019.230). Completion of the electronic survey was viewed as consent to participate.

In particular the start of electronic survey contained the following phrase: "By completing the survey we assume you give informed consent to use your anonymous responses in our analysis and publications."

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID Shivanthan Shanthikumar https://orcid.org/0000-0001-6000-3180

Anne Stone https://orcid.org/0000-0001-6004-4257

Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT

Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children's Oncology Group Report

Haematopoietic Stem Cell Transplantation

Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution

Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation

Assessment of late mortality risk after allogeneic blood or marrow transplantation performed in childhood

Pulmonary complications in pediatric and adolescent patients following allogeneic hematopoietic cell transplantation

Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: non-infectious and long-term complications. Pediatr Blood Cancer

Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation

Pulmonary complications of haematopoietic cell transplantation in children

Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation

Lung injury following hematopoietic cell transplantation

The lung as a target organ of graft-versus-host disease

Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation

Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation

Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome

Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Late acute and chronic graftversus-host disease after allogeneic hematopoietic cell transplantation

Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation

Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation

Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation

A "window of opportunity" for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease

Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT

Value of screening spirometry for early diagnosis of bronchiolitis obliterans syndrome in children after allogeneic hematopoietic stem cell transplantation

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

Lung function after allogeneic hematopoietic stem cell transplantation in children: a longitudinal study in a population-based cohort

Small airways dysfunction in long-term survivors of pediatric stem cell transplantation

Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally

Early lung development: lifelong effect on respiratory health and disease

Pulmonary complications of pediatric hematopoietic cell transplantation. A National Institutes of Health Workshop Summary

Surveillance for pulmonary complications of pediatric hemopoetic stem cell transplantation -An International Survey of Current Clinical Practices. A52 Diffuse Lung Disease, ILD, Drug Induced Lung Disease

Australasian Bone Marrow Transplant Recipient Registry Centres

Foundation for Accrediation of Cellular Therapy. Official listing of FACT-accredited organizations

Lung clearance index for early detection of pulmonary complications after allo-HSCT in children

Long-term complications after hematopoietic cell transplantation

ASBMT practice guidelines committee survey on long-term follow-up clinics for hematopoietic cell transplant survivors

Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 5.0. Children's Oncology Group